洪永贵 - Department of Internal Medicine, Anyang Tumor Hospital

基本信息

浏览量：17

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 74 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Anlotinib Combined with Benmelstobart As a Chemo-Free First-Line Treatment in Advanced Esophageal Squamous Cell Carcinoma: an Exploratory Multicenter, Single-Arm Phase II Clinical Trial

Xiangrui Meng,Xiuli Yang,Yonggui Hong, Wenkang Wang,Zhiye Zhang,Jin Xia, Yunfang Chen,Yue Zhou,Taiying Lu,Min Song, Zhengzheng Shan,Tao Wu, Weilong Wu, Ling Shen,Lulu Guan, Mingying Ma, Lisen Wang, Xi Luo,Dao Xin,Yihui Ma,Guozhong Jiang,Yu Qi,Binghua Jiang, Daoyu Zhang, Biao Hu, Xiaoying Wu, Zuofu Peng,Feng Wang

Molecular Cancerno. 1 (2025): 1-13

引用0浏览0WOS引用

Feasibility and Tolerability of Anlotinib Plus PD-1 Blockades As Rechallenge Immunotherapy in Previously Treated Advanced ESCC: a Retrospective Study

Yonggui Hong,Jun Liu,Ping Lu,Zhiwei Chang,Guifang Zhang,Xiumei Ma, Wei Liang, Yongjing Tian,Jin Xia,Heng Cao,Jing Huang

ONCOLOGIST（2024）

引用0浏览0WOS引用

First-line Benmelstobart Plus Anlotinib and Chemotherapy in Advanced or Metastatic/recurrent Esophageal Squamous Cell Carcinoma: a Multi-Center Phase 2 Study

Ning Li,Jin Xia,Xiaohui Gao,Jianwei Zhou,Yonggui Hong,Donghai Cui, Xuesong Zhao,Tao Wu,Yanzhen Guo,Junsheng Wang,Suxia Luo

SIGNAL TRANSDUCTION AND TARGETED THERAPYno. 1 (2024)

引用0浏览0WOSNATURE引用

Update Results of Anlotinib Combined with TQB2450 (PD-L1 Blockade) As First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma (ESCC): A Single-Arm, Multicenter, Open-Label Phase II Clinical Trial

Xiangrui Meng,Xiuli Yang,Yong-Gui Hong,Zhiye Zhang,Jin Xia,Yunfang Chen,Tao Wu,Zheng-Zheng Shan,Qingxia Fan,Feng Wang

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

The Feasibility and Tolerability of Anlotinib Plus PD-1 Blockades among Patients with Previously Immunotherapy Treated Advanced Esophageal Squamous Cell Carcinoma (ESCC): Update Results of a Retrospective Exploratory Study

Jing Huang,Yong-Gui Hong,Jun Liu,Ping Lu, Zhiwei Chang,Guifang Zhang,Xiumei Ma, Wei Liang, Yongjing Tian, Jin Xia, Heng Cao

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

Camrelizumab Plus Apatinib after Progression on Immune Checkpoint Inhibitors in Patients with Advanced Esophageal Squamous Cell Carcinoma (CAP 02 Re-challenge): A Single-Arm Multicenter, Phase II Trial

Xiangrui Meng,Junsheng Wang,Jin Xia,Tao Wu,Zhiquan Luo,Yong-Gui Hong,Ping Lu,Yanzhen Guo,Yinghua Ji,Min Zhang,Liuzhong Yang, Peng Cheng,Wenchang Liang,Zhengzheng Shan,Qingxia Fan,Feng Wang

Journal of Clinical Oncologyno. 3_suppl (2024): 364-364

引用1浏览0引用

Efficacy and Safety of Camrelizumab Plus Apatinib in Patients with Advanced Esophageal Squamous Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors (CAP 02 Re-challenge): a Single-Arm, Phase II Study

Xiangrui Meng,Junsheng Wang,Jin Xia,Tao Wu,Zhiquan Luo,Yonggui Hong,Ping Lu,Yanzhen Guo,Yinghua Ji,Min Zhang,Liuzhong Yang, Peng Cheng,Wenchang Liang,Zhengzheng Shan,Yue Zhou,Mingyue Wang,Taiying Lu,Min Song,Hong Zong,Lijie Song,Wenkang Wang,Lulu Guan, Yanke Li,Jianxiang Xing, Siyuan Xing,Han Wu, Jingwen Chu,Xi Luo,Yao Lu,Dao Xin, Aijia Li,Binghua Jiang,Shenglei Li,Guozhong Jiang,Qingxia Fan, Feng Zhao,Rongrong Zheng, Wenqing Zhu,Zhiguo Hou, Yun Jia,Feng Wang

European Journal of Cancer (2024): 114328-114328

引用0浏览0WOS引用

A Single-Arm, Open-Label Phase II Clinical Trial of SHR-1210 (camrelizumab) in Combination with Nimotuzumab in the Second-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma

Feng Wang,Jin Xia,Xiangrui Meng, Yinghua Ji,Xiuli Yang,Yong-Gui Hong,Junsheng Wang, Donghai Cui,Zhiquan Luo

JOURNAL OF CLINICAL ONCOLOGY（2024）

引用0浏览0引用

基于非正交解耦原理的紧凑型高压交流磁饱和限流器研究

袁佳歆,叶丛韬,陈鹤冲,洪永贵,郑元坤

高电压技术（2023）

引用0浏览0引用

Update Results of Paclitaxel and Cisplatin in Combination with Anlotinib As First-Line Regimen for Patients with Advanced ESCC: A Multicenter, Single-Arm, Open-Label Phase Ⅱ Clinical Trial

Ning Li,Tao Wu,Yong-Gui Hong,Yanzhen Guo,Yufeng Cheng,Baosheng Li,Junsheng Wang,Suxia Luo

Journal of Clinical Oncology（2023）

引用1浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn

YongGui Hong(洪永贵)

论文共 74 篇作者统计合作学者相似作者